Therefore, Src is probably not the lone dominant transforming factor in most cancers, but significantly contributes to cancer progression, resistance, and metastasis, and Src is overexpressed or hyperactivated in many human neoplasms, including colorectal, breast, pancreas, prostate, and lung as well as different types of sarcomas, glioma and melanoma. Here, SRC is linked to glioma.